Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
Open Access
- 19 July 2022
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 122, 793-801
Abstract
No abstract availableKeywords
All Related Versions
This publication has 36 references indexed in Scilit:
- Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 VaccineNew England Journal of Medicine, 2021
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysisNature Medicine, 2021
- Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)The Lancet, 2021
- N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2eLife, 2021
- Spike-antibody waning after second dose of BNT162b2 or ChAdOx1The Lancet, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccinationScience Immunology, 2021
- T Cell Memory: Understanding COVID-19Immunity, 2021
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialThe Lancet, 2020